|
시장보고서
상품코드
2117967
항비만제 : 시장 인사이트, 경쟁 구도 및 시장 예측(2034년)Anti-Obesity Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
개요:
- 세계 항비만제 시장은 2025년에 458억 달러 규모에 달했으며, 2034년까지 1,486억 달러에 달할 것으로 전망됩니다.
- 2026년부터 2034년까지의 예측 기간 동안 전 세계 비만 및 과체중 유병률의 증가, GIP/GLP-1 이중 작용제 및 신흥 삼중 작용제 요법의 상업적 부상, 심혈관 위험 감소 및 폐쇄성 수면무호흡증에 대한 적응증 확대,그리고 투여 빈도가 적은 제제 및 경구용 제제에 대한 지속적인 파이프라인 투자가 뒷받침되어, 해당 시장은 연평균 성장률(CAGR) 14.0%로 확대될 것으로 전망됩니다.
- 약제 분류별로는 2025년에 듀얼/트리플 작용제 부문이 48%의 점유율을 차지하며 항비만제 시장을 주도했습니다.
- 투여 경로별로는 2025년에 피하 주사·주사제 부문이 88%의 점유율을 차지하며 항비만제 시장을 독점했으나, 경구제 부문이 가장 빠르게 성장한 투여 경로가 되었습니다.
- 적응증별로는 2025년에 만성 체중 관리(비만/과체중) 부문이 72%의 점유율을 차지하며 항비만제 시장을 주도했습니다.
- 유통 채널별로는 2025년에 소매 약국 부문이 54%의 점유율로 항비만제 시장을 독점한 반면, 온라인 및 원격의료 약국 채널이 가장 빠르게 성장하는 유통 채널이 되었습니다.
- 2025년 시점에서 북미는 항비만제 시장에서 62%라는 최대 점유율을 차지했으나, 2034년까지 아시아태평양이 가장 빠른 성장세를 보일 것으로 예상됩니다.
항비만제는 비만이나 과체중 치료에 사용되는 약리학적 제제로, 일반적으로 저칼로리 식단이나 운동량 증가와 병행하여 피하 주사 또는 경구 투여로 투여됩니다. 그 범주에는 노보 노디스크의 ‘웨고비(세마글루타이드)’ 및 ‘삭센다(릴라글루타이드)’를 포함한 단일 GLP-1 수용체 작용제,이중 및 삼중 작용제(Eli Lilly의 GIP/GLP-1 수용체 이중 작용제 ‘제프바운드(tirzepatide)’ 등)와,일라이 릴리의 ‘레타토르티드’나 보링거 인겔하임 및 젤랜드 파마의 ‘서보두티드’와 같은 개발 중인 후보 약물; GLP-1/아밀린 병용제에는 노보 노르디스크의 임상시험용 약물 ‘카그리세마(CagriSema)’ 등이 포함됩니다;멜라노코르틴-4 수용체(MC4R) 작용제에는 희귀 유전성 비만 증후군을 대상으로 한 리듬 파마슈티컬스(Rhythm Pharmaceuticals)의 ‘임시브리(Imcivree, 세토멜라노티드)’ 등이 포함됩니다;비인크레틴계 병용 경구약으로는 Currax Pharmaceuticals의 ‘Qsymia(펜터민·토피라메이트)’ 및 ‘Contrave(날트렉손·부프로피온)’;리파제 억제제로는 오르리스타트; 그리고 성장호르몬 방출 인자 아날로그로는 Theratechnologies의 ‘Egrifta(테사모렐린)’ 등이 있습니다. 이 시장은 만성 체중 관리, 심혈관 및 대사 위험 감소, 폐쇄성 수면무호흡증, 그리고 희귀 유전성 비만의 적응증을 포괄합니다.
항비만제 시장의 주요 성장요인
- 전 세계적으로 비만 및 과체중 유병률이 증가하고 있으며, 세계보건기구(WHO)의 추정에 따르면 전 세계 성인의 약 8명 중 1명이 비만 상태인 것으로 알려져 있어, 약물을 통한 체중 관리에 대한 폭넓은 수요가 지속되고 있습니다.
- GIP/GLP-1 이중 작용제 및 새롭게 등장한 삼중 작용제 요법의 상업적 성공을 들 수 있습니다. 그 대표적인 예로, Eli Lilly의 ‘제프바운드’가 2025년에 229억 달러의 매출을 기록하며 전년 대비 188.7% 증가했고, 매출 기준으로 Novo Nordisk의 ‘웨고비’를 제치고 비만 치료제 1위로 도약했습니다.
- 체중 감량뿐만 아니라 심혈관 위험 감소 및 폐쇄성 수면무호흡증에 대한 적응증 확대가 진행되고 있으며, 그 일례로 ‘웨고비’의 심혈관 위험 감소에 대한 승인이나,‘제프바운드’가 2025년 11월 비만을 동반한 성인의 중등도에서 중증 폐쇄성 수면무호흡증에 대한 적응증 확대를 들 수 있습니다.
- 암젠의월 1회 투여 제제인 ‘마리타이드’나, 일라이 릴리의 임상시험 중인 경구용 GLP-1 작용제 ‘올포글리프론’ 등, 투여 빈도가 낮은 제제나 경구용 제제에 대한 파이프라인 투자가 지속되면서 환자의 편의성과 접근성이 확대되고 있습니다.
- 기존의 임상 소개 경로를 넘어, 환자의 접근성과 항비만 약물 요법에 대한 인식을 확대하는 소비자 직접 판매(DTC) 및 원격의료(텔레헬스) 유통 채널이 확대되고 있습니다.
- Eli Lilly가 발표한 65억 달러 규모의 휴스턴 제조 시설 등, 주요 제조사들의 생산능력에 대한 투자가 증가하고 있어 지속적인 세계적 수요와 기존의 공급 제약에 대응하고 있습니다.
- GLP-1/아밀린 병용요법이나 GLP-1/GIP/글루카곤 삼중 작용제 등 차세대 다중 수용체 작용제 기전에 대한 지속적인 투자가 이루어지고 있으며, 이러한 치료법들은 비만 수술에 버금가는 체중 감량 효과를 보여주고 있습니다.
항비만제 시장 성장에 기여하는 요인
시장 촉진요인
세계 비만 및 과체중 유병률의 증가
항비만제 시장의 근본적인 촉진요인은 전 세계 비만 및 과체중 유병률의 상승입니다. 세계보건기구(WHO)의 추정에 따르면, 전 세계 성인의 약 8명 중 1명이 비만을 앓고 있습니다. 비만은 2형 당뇨병, 심혈관질환, 폐쇄성 수면 무호흡 증후군 및 기타 수많은 동반 질환과 밀접한 관련이 있으며, 효과적인 약물을 통한 체중 관리는 단순한 선택적 개입이 아닌 공중 보건상의 우선 과제로 그 중요성이 커지고 있습니다. 도시화, 식생활의 변화, 앉아 있는 생활 방식을 배경으로 전 세계 비만 및 과체중 유병률이 계속 증가함에 따라, 약물 기반 체중 관리의 대상이 되는 인구도 이에 따라 확대되고 있으며, 예측 기간 동안 시장의 모든 약물 군에 걸쳐 수요가 유지될 것으로 전망됩니다.
GIP/GLP-1 이중 작용제 및 삼중 작용제 요법의 상업적 부상
GIP/GLP-1 이중 작용제 및 새로운 삼중 작용제 요법의 상업적 부상은 항비만제 시장에서 결정적인 구조적 변화를 나타냅니다. Eli Lilly의 ‘제프바운드(tirzepatide)’는 2025년에 229억 달러의 매출을 기록하며 전년 대비 188.7% 증가했습니다. 이로써 2025년 매출액이 186억 달러에 달한 노보 노르디스크(Novo Nordisk)의 ‘웨고비(Wegovy)’를 제치고, 매출 기준 항비만제 시장 1위로 도약했습니다. 이러한 순위 변동은 2024년 12월에 보고된 SURMOUNT-5 임상시험을 포함한 직접 비교 임상 데이터에 의해 뒷받침되고 있습니다. 해당 임상시험에서 72주 동안 ‘제프바운드’는 평균 20.2%의 체중 감소를 달성한 반면, ‘웨고비’는 13.7%에 그쳤습니다. Eli Lilly와 Novo Nordisk가 Eli Lilly의 트리플 작용제 ‘레타톨티드’와 Novo Nordisk의 아밀린 복합제 ‘카그리세마’ 등,차세대 다중 수용체 작용제 후보에 대한 투자를 지속하고 있는 만큼, 듀얼 및 트리플 작용제의 작용기전은 예측 기간 동안 시장에서 가장 규모가 크고 역동적인 약물 군으로서의 지위를 유지할 것으로 예상됩니다.
시장 제약요인
비만 치료제 시장은 성장을 둔화시키는 몇 가지 상호 연관된 제약요인에 직면해 있습니다. 브랜드 GLP-1, 이중 작용제 및 다중 수용체 작용제 요법의 높은 비용에 더해, 특히 체중 관리 적응증에 대한 보험 적용 범위가 제각각이고 일관성이 부족하다는 점이 더 광범위한 보급을 방해하고, 환자에게 막대한 본인 부담금을 안겨주고 있습니다. 환자의 복약 순응도 및 치료 지속과 관련된 과제는 시장 전체에 영향을 미치고 있으며, 실제 임상 데이터에 따르면 상당수의 환자가 치료 시작 후 1년 이내에 항비만제 치료를 중단하고 있는데, 그 대부분은 위장관 부작용, 비용, 또는 치료에 대한 피로감과 관련이 있습니다. 브랜드 제품인 세마글루티드 및 틸제파티드 제품의 조제 의약품이나 무허가 모방품이 범람하고 있는 것은 안전상의 우려를 야기하고, 원개발사에 상업적 혼란을 초래하며, 브랜드 제품 공급이 부족한 기간 동안의 시장 역학을 복잡하게 만들고 있습니다. 2027년 미국에서 발효될 노보 노르디스크의 세마글루타이드에 대한 향후 정부의 약가 협상은 가격 책정 및 수익 예측에 상업적 불확실성을 초래하고 있습니다. 치료 중단 후 체중이 다시 증가하는 경향이 충분히 입증된 점을 감안할 때, 체중 감량 효과를 유지하기 위해서는 장기간에 걸친 지속적인 치료가 필요하기 때문에 장기적인 치료 순응도, 비용의 지속가능성, 그리고 의료 제도 예산에 미치는 영향에 대한 의문이 제기되고 있습니다. 이러한 요인들이 복합적으로 작용하여 도입 속도가 완만해지고 있으며, 제약사는 성장을 유지하기 위해 합리적인 가격, 안정적인 공급, 그리고 장기적인 치료 순응도 지원을 입증해야 할 필요가 있습니다.
자주 묻는 질문
목차
제1장 항비만제 시장 : 소개
제2장 항비만제 시장 : 주요 요약
제3장 항비만제 시장 : 주요 요인 분석
제4장 AI, 지정학, 무역 및 경제 동향
제5장 규제 분석
제6장 Porter's Five Forces 분석
제7장 항비만제 시장 : 평가
제8장 항비만제 시장 : 경쟁 구도
제9장 항비만제 시장 : 스타트업 자금 조달 및 투자 동향
제10장 항비만제 시장 : 기업 개요 및 제품 프로파일
제11장 KOL의 견해
제12장 프로젝트 접근법
제13장 DelveInsight 소개
제14장 면책사항 및 문의
KSM 26.08.31Anti-Obesity Drugs Market Summary
Overview:
- The global anti-obesity drugs market was valued at USD 45.8 billion in 2025 and is projected to reach USD 148.6 billion by 2034.
- The market is expected to expand at a CAGR of 14.0% during the forecast period 2026-2034, supported by the rising global prevalence of obesity and overweight, the commercial ascent of dual GIP/GLP-1 and emerging triple agonist therapies, expanding indications into cardiovascular risk reduction and obstructive sleep apnea, and continued pipeline investment in less-frequent-dosing and oral formulations.
- By drug class, the dual/triple agonist segment dominated the anti-obesity drugs market with a 48% share in 2025.
- By route of administration, the subcutaneous/injectable segment dominated the anti-obesity drugs market with an 88% share in 2025, while the oral segment represented the fastest-growing route of administration.
- By indication, the chronic weight management (obesity/overweight) segment dominated the anti-obesity drugs market with a 72% share in 2025.
- By distribution channel, the retail pharmacy segment dominated the anti-obesity drugs market with a 54% share in 2025, while online and telehealth pharmacy channels represented the fastest-growing distribution channel.
- North America accounted for the largest share of the anti-obesity drugs market at 62% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.
Anti-obesity drugs are pharmacological agents used to treat obesity and overweight, typically in conjunction with a reduced-calorie diet and increased physical activity, delivered via subcutaneous injection or oral administration. The scope encompasses single GLP-1 receptor agonists, including Novo Nordisk's Wegovy (semaglutide) and Saxenda (liraglutide); dual and triple agonists, including Eli Lilly's Zepbound (tirzepatide), a dual GIP/GLP-1 receptor agonist, and pipeline candidates such as Eli Lilly's retatrutide and Boehringer Ingelheim and Zealand Pharma's survodutide; GLP-1/amylin combinations, including Novo Nordisk's investigational CagriSema; melanocortin-4 receptor (MC4R) agonists, including Rhythm Pharmaceuticals' Imcivree (setmelanotide) for rare genetic obesity syndromes; non-incretin combination oral drugs, including Currax Pharmaceuticals' Qsymia (phentermine-topiramate) and Contrave (naltrexone-bupropion); lipase inhibitors, including orlistat; and growth hormone-releasing factor analogs, including Theratechnologies' Egrifta (tesamorelin). The market spans chronic weight management, cardiometabolic risk reduction, obstructive sleep apnea, and rare genetic obesity indications.
Anti-Obesity Drugs Market Key Growth Drivers
- Rising global prevalence of obesity and overweight, with the World Health Organization estimating that nearly 1 in 8 adults worldwide live with obesity, sustaining broad-based demand for pharmacological weight management.
- Commercial ascent of dual GIP/GLP-1 and emerging triple agonist therapies, exemplified by Eli Lilly's Zepbound generating USD 22.9 billion in 2025 sales, a 188.7% increase over the prior year, and overtaking Novo Nordisk's Wegovy as the leading obesity drug by revenue.
- Expanding regulatory indications beyond weight loss alone into cardiovascular risk reduction and obstructive sleep apnea, exemplified by Wegovy's cardiovascular risk reduction approval and Zepbound's November 2025 expanded indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
- Continued pipeline investment in less-frequent-dosing and oral formulations, including Amgen's monthly-dosing MariTide and Eli Lilly's investigational oral GLP-1 agonist orforglipron, expanding patient convenience and access.
- Growing direct-to-consumer and telehealth distribution channels that expand patient access and awareness of anti-obesity drug therapy beyond traditional clinical referral pathways.
- Rising manufacturing capacity investment by leading manufacturers, including Eli Lilly's announced USD 6.5 billion Houston manufacturing facility, addressing sustained global demand and prior supply constraints.
- Sustained investment in next-generation multi-receptor agonist mechanisms, including GLP-1/amylin combinations and GLP-1/GIP/glucagon triple agonists, that demonstrate weight loss efficacy approaching bariatric surgery outcomes.
Key Companies in Anti-Obesity Drugs Market
The leading participants in the anti-obesity drugs market include the following:
- Novo Nordisk A/S
- Eli Lilly and Company
- Amgen Inc.
- Roche Holding AG
- Boehringer Ingelheim International GmbH
- Rhythm Pharmaceuticals, Inc.
- Viking Therapeutics, Inc.
- Structure Therapeutics Inc.
- Zealand Pharma A/S
- Currax Pharmaceuticals LLC
Factors Contributing to the Growth of the Anti-Obesity Drugs Market
Market Drivers
Rising Global Prevalence of Obesity and Overweight
The foundational driver of the anti-obesity drugs market is the rising global prevalence of obesity and overweight, with the World Health Organization estimating that nearly 1 in 8 adults worldwide are living with obesity. Obesity is strongly associated with type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and numerous other comorbidities, positioning effective pharmacological weight management as a growing public health priority rather than an elective intervention. As the global prevalence of obesity and overweight continues to rise, driven by urbanization, dietary shifts, and sedentary lifestyles, the population eligible for pharmacological weight management expands correspondingly, sustaining demand across the market's full range of drug classes throughout the forecast period.
Commercial Ascent of Dual GIP/GLP-1 and Triple Agonist Therapies
The commercial ascent of dual GIP/GLP-1 and emerging triple agonist therapies represents the defining structural development in the anti-obesity drugs market. Eli Lilly's Zepbound (tirzepatide) generated USD 22.9 billion in sales in 2025, a 188.7% increase over the prior year, overtaking Novo Nordisk's Wegovy, which reached USD 18.6 billion in 2025 sales, as the leading obesity drug by revenue. This shift reflects head-to-head clinical evidence, including the SURMOUNT-5 trial reported in December 2024, in which Zepbound achieved 20.2% average weight loss compared to 13.7% for Wegovy over 72 weeks. As Eli Lilly and Novo Nordisk continue to invest in next-generation multi-receptor agonist candidates, including Eli Lilly's triple agonist retatrutide and Novo Nordisk's amylin-combination CagriSema, dual and triple agonist mechanisms are expected to sustain their position as the market's largest and most dynamic drug class across the forecast period.
Market Restraints
The anti-obesity drugs market faces several interrelated restraints that temper its growth. The high cost of branded GLP-1, dual agonist, and multi-receptor agonist therapies, combined with variable and inconsistent insurance coverage for weight management indications specifically, constrains broader adoption and creates substantial patient out-of-pocket cost burden. Patient adherence and persistence challenges affect the market broadly, with real-world data indicating that a meaningful share of patients discontinue anti-obesity drug therapy within the first year of treatment, often related to gastrointestinal side effects, cost, or treatment fatigue. The proliferation of compounded and unauthorized copies of branded semaglutide and tirzepatide products has introduced safety concerns and created commercial disruption for originator manufacturers, complicating market dynamics during periods of branded product supply constraint. Upcoming government drug pricing negotiations for Novo Nordisk's semaglutide, effective in the United States in 2027, create commercial uncertainty for pricing and revenue projections. The requirement for continued long-term therapy to sustain weight loss outcomes, given the well-documented pattern of weight regain following treatment discontinuation, raises questions about long-term treatment adherence, cost sustainability, and health system budget impact. Together, these factors moderate the pace of adoption and require manufacturers to demonstrate affordability, supply reliability, and long-term adherence support to sustain growth.
Anti-Obesity Drugs Market Segment Analysis
The global anti-obesity drugs market by drug class (single GLP-1 receptor agonists, dual/triple agonists, GLP-1/amylin combinations, melanocortin-4 receptor (MC4R) agonists, non-incretin combination oral drugs, lipase inhibitors, and others), by route of administration (subcutaneous/injectable and oral), by indication (chronic weight management [obesity/overweight], obesity with cardiometabolic risk reduction, obstructive sleep apnea with obesity, rare genetic obesity syndromes, and others), by distribution channel (retail pharmacy, hospital pharmacy, and online/telehealth pharmacy), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).
By Drug Class
Dominant Subsegment: Dual/Triple Agonists.
The dual/triple agonist category is expected to dominate the market. The segment accounted for a 48% share of the anti-obesity drugs market in 2025. This class, led by Eli Lilly's Zepbound (tirzepatide), a dual GIP/GLP-1 receptor agonist, is the leading drug class because it has demonstrated superior weight loss efficacy relative to single GLP-1 receptor agonist therapy in head-to-head clinical trials, translating directly into commercial share gains, with Zepbound's 2025 sales growth of 188.7% substantially outpacing the growth of single-agonist competitors. The dominance of the segment reflects the scale of Eli Lilly's commercial investment, the depth of clinical evidence supporting superior efficacy, and the continued advancement of triple agonist candidates such as retatrutide that extend the mechanism further. While single GLP-1 receptor agonists, led by Novo Nordisk's Wegovy, remain a substantial and clinically important category, and GLP-1/amylin combinations and MC4R agonists serve important complementary and niche roles respectively, the demonstrated efficacy advantage and commercial momentum of dual and triple agonist mechanisms sustain the leadership of the segment across the forecast period.
By Route of Administration
Dominant Subsegment: Subcutaneous/Injectable.
The subcutaneous/injectable category is expected to dominate the market. The subcutaneous/injectable segment accounted for an 88% share of the anti-obesity drugs market in 2025. Injectable therapy, including both leading commercial products, Wegovy and Zepbound, is the leading route of administration because weekly self-injection remains the standard formulation for the highest-efficacy, highest-revenue anti-obesity drugs currently marketed. The dominance of the segment reflects the continued predominance of injectable delivery among the top-selling branded anti-obesity drugs and the fact that the newly approved oral semaglutide formulation and Eli Lilly's investigational oral orforglipron remain in the earliest stages of commercial rollout or clinical development, respectively. The oral route of administration represented the fastest-growing route in 2025, driven by the late-2025 FDA approval of an oral semaglutide pill for chronic weight management and the anticipated future launch of orforglipron, and is expected to gain share progressively as additional oral candidates reach the market across the forecast period.
Anti-Obesity Drugs Market Region Analysis
Dominant Region: North America
North America accounted for a 62% share of the global anti-obesity drugs market in 2025, representing the highest regional market share globally. The leadership of the region reflects the concentration of Wegovy and Zepbound commercial revenue in the United States, driven by high obesity prevalence, expanding commercial and government insurance coverage for weight management indications, and the aggressive direct-to-consumer and telehealth commercial strategies both Novo Nordisk and Eli Lilly have built around their franchises. The United States is the largest national market, supported by high healthcare expenditure, the concentration of leading manufacturers, and the depth of FDA regulatory activity extending anti-obesity drug indications into cardiovascular and sleep apnea comorbidities. The concentration of commercial revenue, reimbursement structures, and manufacturer investment reinforce the position of North America as the largest regional market across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is projected to register the fastest compound annual growth rate through 2034. The region faces a rapidly escalating obesity burden alongside expanding healthcare access and rising disposable income, with China, Japan, and India representing substantial addressable populations for anti-obesity drug therapy. Novo Nordisk launched Wegovy in India in June 2025, marking the drug's first approval in the country both for chronic weight management and for cardiovascular risk reduction, while Eli Lilly's Mounjaro has seen strong early uptake in the Indian market. As regional manufacturing partnerships, government healthcare investment, and rising consumer awareness of pharmacological weight management continue to develop, the region increases its adoption of anti-obesity drugs from a growing base, positioning Asia-Pacific as the fastest-growing regional market across the forecast period.
Regional Commentary
North America
North America leads the market, supported by the concentration of Wegovy and Zepbound commercial revenue, expanding insurance coverage, and aggressive direct-to-consumer commercial strategies. The United States dominates the region through its concentration of manufacturers and its outsized share of global anti-obesity drug revenue.
Europe
Europe is a significant market shaped by national health technology assessment pathways, rising obesity prevalence, and the presence of leading manufacturers including Novo Nordisk, Boehringer Ingelheim, and Zealand Pharma. Germany, the United Kingdom, France, Italy, and Spain are the principal national markets, and the region continues to navigate reimbursement negotiations that shape the pace of anti-obesity drug adoption relative to the more commercially permissive United States market.
Asia-Pacific
Asia-Pacific is the fastest-growing region, driven by the scale of the obesity-affected population in China and India, expanding healthcare access, and recent market entries such as Novo Nordisk's 2025 launch of Wegovy in India.
Rest of World
The Rest of World, spanning Latin America, the Middle East, and Africa, represents an emerging opportunity as obesity prevalence rises and healthcare access expands, though adoption of advanced, higher-cost drug classes remains concentrated in leading urban centers and private healthcare systems.
Anti-Obesity Drugs Market Competitive Landscape
The global anti-obesity drugs market is classified as Consolidated. Novo Nordisk and Eli Lilly together hold a dominant share of commercial revenue, effectively forming a duopoly at the center of the market, while a broader group of pharmaceutical and biotechnology companies advance differentiated pipeline candidates targeting novel mechanisms, dosing intervals, and administration routes. Competition centers on the breadth and depth of the multi-receptor agonist pipeline, clinical evidence supporting comorbidity-specific indications, manufacturing capacity to meet sustained demand, and the pace of oral and less-frequent-dosing formulation development. The competitive landscape is evaluated across the following dimensions:
- Market concentration: Consolidated, with Novo Nordisk and Eli Lilly together dominating commercial revenue, alongside Amgen, Roche, Boehringer Ingelheim, Rhythm Pharmaceuticals, Viking Therapeutics, Structure Therapeutics, Zealand Pharma, and Currax Pharmaceuticals competing across pipeline and niche established drug classes.
- Leading players: Eli Lilly leads through its Zepbound franchise, having overtaken Novo Nordisk's Wegovy in 2025 commercial revenue and captured a majority of new US patient starts by mid-2025; Novo Nordisk maintains a leading position through Wegovy and its CagriSema and amycretin pipeline; and Rhythm Pharmaceuticals leads the rare genetic obesity niche through Imcivree.
- Geographic reach: Novo Nordisk and Eli Lilly operate global commercial and regulatory organizations, while specialist and pipeline-stage companies including Rhythm Pharmaceuticals, Viking Therapeutics, and Structure Therapeutics maintain more concentrated footprints centered on specific mechanisms and geographies.
- Product portfolio strength: Competitive advantage rests on the breadth across single agonist, dual/triple agonist, and amylin-combination mechanisms, and on the depth of clinical evidence supporting expanded cardiovascular, sleep apnea, and other comorbidity-specific indications.
- Pipeline strength: Development is concentrated in triple agonist candidates, monthly and less-frequent dosing formulations, and oral small-molecule GLP-1 agonists, with Amgen, Viking Therapeutics, Structure Therapeutics, Zealand Pharma, Hanmi Pharmaceutical, Kailera Therapeutics, and Metsera all advancing differentiated late-stage candidates.
- Strategic partnerships: Collaboration spans licensing and co-development agreements for next-generation candidates, exemplified by Boehringer Ingelheim's partnership with Zealand Pharma on survodutide, and manufacturing capacity partnerships addressing sustained global demand.
- M&A activity: Consolidation has shaped the field, exemplified by Roche's acquisition of Carmot Therapeutics to establish an obesity drug pipeline including CT-388 and CT-996, reflecting the broader pattern of larger pharmaceutical companies acquiring specialized obesity drug developers to establish or expand competitive position.
- Innovation focus: Innovation is concentrated in triple agonist mechanisms, GLP-1/amylin combinations, monthly-dosing formulations that reduce injection frequency, and oral small-molecule GLP-1 agonists that eliminate the need for injection.
- Regulatory standing: FDA approval of expanded comorbidity-specific indications, exemplified by Zepbound's November 2025 obstructive sleep apnea approval and Wegovy's cardiovascular risk reduction approval, are decisive competitive credentials that extend prescribing beyond weight loss alone.
Anti-Obesity Drugs Market Recent Developmental Activities
- In November 2025, the FDA approved an expanded indication for Eli Lilly's Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, based on SURMOUNT-OSA trial data. Strategic significance: the approval extended Zepbound's addressable market beyond weight management into a major sleep medicine indication.
- In late 2025, the FDA approved an oral semaglutide formulation for chronic weight management. Strategic significance: the approval introduced the first oral formulation of a leading anti-obesity drug, expanding access beyond injection-tolerant patients.
Anti-Obesity Drugs Market Segmentation
Anti-Obesity Drugs Market Assessment by Drug Class
- Single GLP-1 Receptor Agonists
- Dual/Triple Agonists
- GLP-1/Amylin Combinations
- Melanocortin-4 Receptor (MC4R) Agonists
- Non-Incretin Combination Oral Drugs
- Lipase Inhibitors
- Others
Anti-Obesity Drugs Market Assessment by Route of Administration
- Subcutaneous/Injectable
- Oral
Anti-Obesity Drugs Market Assessment by Indication
- Chronic Weight Management (Obesity/Overweight)
- Obesity with Cardiometabolic Risk Reduction
- Obstructive Sleep Apnea with Obesity
- Rare Genetic Obesity Syndromes
- Others
Anti-Obesity Drugs Market Assessment by Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online/Telehealth Pharmacy
Anti-Obesity Drugs Market Assessment by Geography
- North America
- United States Anti-Obesity Drugs Market Size in USD million (2023-2034)
- Canada Anti-Obesity Drugs Market Size in USD million (2023-2034)
- Mexico Anti-Obesity Drugs Market Size in USD million (2023-2034)
- Europe
- Germany Anti-Obesity Drugs Market Size in USD million (2023-2034)
- United Kingdom Anti-Obesity Drugs Market Size in USD million (2023-2034)
- France Anti-Obesity Drugs Market Size in USD million (2023-2034)
- Italy Anti-Obesity Drugs Market Size in USD million (2023-2034)
- Spain Anti-Obesity Drugs Market Size in USD million (2023-2034)
- Rest of Europe Anti-Obesity Drugs Market Size in USD million (2023-2034)
- Asia-Pacific
- China Anti-Obesity Drugs Market Size in USD million (2023-2034)
- Japan Anti-Obesity Drugs Market Size in USD million (2023-2034)
- India Anti-Obesity Drugs Market Size in USD million (2023-2034)
- Australia Anti-Obesity Drugs Market Size in USD million (2023-2034)
- South Korea Anti-Obesity Drugs Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Anti-Obesity Drugs Market Size in USD million (2023-2034)
- Rest of the World
- Middle East Anti-Obesity Drugs Market Size in USD million (2023-2034)
- Africa Anti-Obesity Drugs Market Size in USD million (2023-2034)
- South America Anti-Obesity Drugs Market Size in USD million (2023-2034)
Key Takeaways from the Anti-Obesity Drugs Market Report Study
- Market size analysis for the current anti-obesity drugs market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key research, clinical, and commercial developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global anti-obesity drugs market.
- Various opportunities available for competitors in the anti-obesity drugs market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current anti-obesity drugs market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for anti-obesity drugs market growth in the future?
Target audience who can benefit from this anti-obesity drugs market report study
- Anti-obesity drug manufacturers
- Research organizations and consulting companies
- Obesity medicine and endocrinology-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in anti-obesity drugs
- Various end-users who want to know more about the anti-obesity drugs market and the latest research developments in the anti-obesity drugs market.
Frequently Asked Questions:
Q1. At what rate is the anti-obesity drugs market expected to grow?
The global anti-obesity drugs market is projected to grow at a compound annual growth rate of 14.0% during the forecast period from 2026 to 2034.
Q2. What is the current and projected size of the anti-obesity drugs market?
The global anti-obesity drugs market was valued at USD 45.8 billion in 2025 and is projected to reach USD 148.6 billion by 2034.
Q3. Which region dominates the anti-obesity drugs market?
North America dominated the anti-obesity drugs market with a 62% share in 2025, driven by the concentration of Wegovy and Zepbound commercial revenue and expanding insurance coverage. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by the scale of the obesity-affected population in China and India and recent market entries such as the 2025 launch of Wegovy in India.
Q4. What are the key factors driving growth in the anti-obesity drugs market?
The principal drivers are the rising global prevalence of obesity and overweight; the commercial ascent of dual GIP/GLP-1 and emerging triple agonist therapies; expanding regulatory indications into cardiovascular risk reduction and obstructive sleep apnea; continued pipeline investment in less-frequent-dosing and oral formulations; and the growth of direct-to-consumer and telehealth distribution channels.
Q5. Who are the major players in the anti-obesity drugs market?
The market is consolidated and led by Novo Nordisk A/S and Eli Lilly and Company, which together dominate commercial revenue, alongside Amgen Inc., Roche Holding AG, Boehringer Ingelheim, Rhythm Pharmaceuticals, Inc., Viking Therapeutics, Inc., Structure Therapeutics Inc., Zealand Pharma A/S, and Currax Pharmaceuticals LLC.
Table of Contents
1. Anti-Obesity Drugs Market Introduction
- 1.1. Scope of the Report
- 1.2. Market Segmentation
- 1.3. Market Overview at a Glance
2. Anti-Obesity Drugs Market Executive Summary
- 2.1. Key Highlights and Market Snapshot
3. Anti-Obesity Drugs Market Key Factors Analysis
- 3.1. Market Drivers
- 3.1.1. Rising Global Prevalence of Obesity and Overweight
- 3.1.2. Commercial Ascent of Dual GIP/GLP-1 and Triple Agonist Therapies
- 3.1.3. Expanding Regulatory Indications Beyond Weight Loss
- 3.1.4. Pipeline Investment in Less-Frequent-Dosing and Oral Formulations
- 3.2. Market Restraints
- 3.2.1. High Cost and Variable Insurance Coverage
- 3.2.2. Patient Adherence and Persistence Challenges
- 3.2.3. Compounded and Unauthorized Product Competition
- 3.3. Market Opportunities
- 3.3.1. Oral Small-Molecule GLP-1 Agonists
- 3.3.2. Monthly and Less-Frequent Dosing Formulations
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1. The United States
- 5.2. Europe
- 5.3. Japan
- 5.4. China
6. Anti-Obesity Drugs Market Porter's Five Forces Analysis
- 6.1. Bargaining Power of Suppliers
- 6.2. Bargaining Power of Consumers
- 6.3. Threat of New Entrants
- 6.4. Threat of Substitutes
- 6.5. Competitive Rivalry
7. Anti-Obesity Drugs Market Assessment
- 7.1. By Drug Class
- 7.1.1. Single GLP-1 Receptor Agonists
- 7.1.2. Dual/Triple Agonists
- 7.1.3. GLP-1/Amylin Combinations
- 7.1.4. Melanocortin-4 Receptor (MC4R) Agonists
- 7.1.5. Non-Incretin Combination Oral Drugs
- 7.1.6. Lipase Inhibitors
- 7.1.7. Others
- 7.2. By Route of Administration
- 7.2.1. Subcutaneous/Injectable
- 7.2.2. Oral
- 7.3. By Indication
- 7.3.1. Chronic Weight Management (Obesity/Overweight)
- 7.3.2. Obesity with Cardiometabolic Risk Reduction
- 7.3.3. Obstructive Sleep Apnea with Obesity
- 7.3.4. Rare Genetic Obesity Syndromes
- 7.3.5. Others
- 7.4. By Distribution Channel
- 7.4.1. Retail Pharmacy
- 7.4.2. Hospital Pharmacy
- 7.4.3. Online/Telehealth Pharmacy
- 7.5. By Geography
- 7.5.1. North America
- 7.5.1.1. United States Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.1.2. Canada Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.1.3. Mexico Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.2. Europe
- 7.5.2.1. Germany Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.2.2. United Kingdom Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.2.3. France Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.2.4. Italy Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.2.5. Spain Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.2.6. Rest of Europe Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.3. Asia-Pacific
- 7.5.3.1. China Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.3.2. Japan Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.3.3. India Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.3.4. Australia Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.3.5. South Korea Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.3.6. Rest of Asia-Pacific Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.4. Rest of the World
- 7.5.4.1. Middle East Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.4.2. Africa Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.4.3. South America Anti-Obesity Drugs Market Size in USD million (2023-2034)
- 7.5.1. North America
8. Anti-Obesity Drugs Market Competitive Landscape
- 8.1. Competitive Analysis
- 8.2. Company Share Analysis (Premium Offering)
9. Anti-Obesity Drugs Market Startup Funding and Investment Trends
10. Anti-Obesity Drugs Market Company and Product Profiles
- 10.1. Novo Nordisk A/S
- 10.1.1. Company Overview
- 10.1.2. Company Snapshot
- 10.1.3. Financial Overview
- 10.1.4. Product Listing
- 10.1.5. Entropy
- 10.2. Eli Lilly and Company
- 10.2.1. Company Overview
- 10.2.2. Company Snapshot
- 10.2.3. Financial Overview
- 10.2.4. Product Listing
- 10.2.5. Entropy
- 10.3. Amgen Inc.
- 10.3.1. Company Overview
- 10.3.2. Company Snapshot
- 10.3.3. Financial Overview
- 10.3.4. Product Listing
- 10.3.5. Entropy
- 10.4. Roche Holding AG
- 10.4.1. Company Overview
- 10.4.2. Company Snapshot
- 10.4.3. Financial Overview
- 10.4.4. Product Listing
- 10.4.5. Entropy
- 10.5. Boehringer Ingelheim International GmbH
- 10.5.1. Company Overview
- 10.5.2. Company Snapshot
- 10.5.3. Financial Overview
- 10.5.4. Product Listing
- 10.5.5. Entropy
- 10.6. Rhythm Pharmaceuticals, Inc.
- 10.6.1. Company Overview
- 10.6.2. Company Snapshot
- 10.6.3. Financial Overview
- 10.6.4. Product Listing
- 10.6.5. Entropy
- 10.7. Viking Therapeutics, Inc.
- 10.7.1. Company Overview
- 10.7.2. Company Snapshot
- 10.7.3. Financial Overview
- 10.7.4. Product Listing
- 10.7.5. Entropy
- 10.8. Structure Therapeutics Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Snapshot
- 10.8.3. Financial Overview
- 10.8.4. Product Listing
- 10.8.5. Entropy
- 10.9. Zealand Pharma A/S
- 10.9.1. Company Overview
- 10.9.2. Company Snapshot
- 10.9.3. Financial Overview
- 10.9.4. Product Listing
- 10.9.5. Entropy
- 10.10. Currax Pharmaceuticals LLC
- 10.10.1. Company Overview
- 10.10.2. Company Snapshot
- 10.10.3. Financial Overview
- 10.10.4. Product Listing
- 10.10.5. Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
